Acquired chemotherapy resistance in ovarian cancer

Integrated genomic analyses of ovarian carcinoma

Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170

Whole–genome characterization of chemoresistant ovarian cancer

Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572

Rethinking ovarian cancer: recommendations for improving outcomes

Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815

Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Norquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 593

Evolution of platinum resistance in high-grade serous ovarian cancer

Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213

Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer

Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 198

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

Stronach, E. A., Chen, M. M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H. S., & Gabra, H. (2011) · Neoplasia · doi:10.1593/neo.111032 · Cited by 138

Epithelial ovarian cancer

Lheureux, S., Gourley, C., Vergote, I. B., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 2,017

Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)

Yang, L., Xie, H., Li, Y., Wang, X., Liu, X., & Mai, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8293 · Cited by 327

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

Zhao, Y., Cao, J., Melamed, A., Worley, M. J., Gockley, A. A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 265

Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers

Mahdy, H. A., Ibrahim, M. K., Metwaly, A. M., Belal, A., Mehany, A. B. M., El‐Gamal, K. M., El-Sharkawy, A., Elhendawy, M. A., Radwan, M. M., ElSohly, M. A., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103422 · Cited by 177

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 162

Acquired resistance in cancer: towards targeted therapeutic strategies

Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151

MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis

Chan, D. W., Yung, M. M. H., Chan, Y.-S., Yang, X., Yang, H., Xu, D., Zhan, J., Chan, K. K. L., Ng, T., & Ngan, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105157 · Cited by 128

Designer Self‐Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer

Yang, Z., Xu, H., & Zhao, X. (2020) · Advanced Science · doi:10.1002/advs.201903718 · Cited by 124

GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients

Li, J., Qi, F., Su, H., Zhang, C., Zhang, Q. H., Chen, Y., Chen, P., Su, L., Chen, Y., Yang, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71571 · Cited by 118

Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Rinne, N., Christie, E. L., Ardasheva, A., Kwok, C. H., Demchenko, N., Low, C. M. R., Tralau, C. J., Fotopoulou, C., & Cunnea, P. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.05 · Cited by 97

The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B

Guo, Q., Wu, Y., Guo, X., Cao, L., Xu, F., Zhao, H., Zhu, J., Wen, H., Ju, X., & Wu, X. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.011 · Cited by 76

Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway

Islam, S. S., & Aboussekhra, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1360-3 · Cited by 74

PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma

Ma, H., Li, Y., Wang, X., Wu, H., Qi, G., Li, R., Yang, N., Gao, M., Shi, Y., Yuan, C., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1415-6 · Cited by 69

Lactate accumulation induces H4K12la to activate super-enhancer-driven RAD23A expression and promote niraparib resistance in ovarian cancer

Lu, B., Chen, S., Guan, X., Chen, X., Du, Y., Yuan, J., Wang, J., Wu, Q., Zhou, L., Huang, X., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02295-w · Cited by 75

Advances in cancer theranostics using organic-inorganic hybrid nanotechnology

Chen, G., Qian, Y., Zhang, H., Ullah, A., He, X., Zhou, Z., Fenniri, H., & Shen, J. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101003 · Cited by 63

The response and resistance to drugs in ovarian cancer cell lines in 2D monolayers and 3D spheroids

Świerczewska, M., Sterzyńska, K., Ruciński, M., Andrzejewska, M., Nowicki, M. O., & Januchowski, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115152 · Cited by 59

Design, synthesis, biological evaluation, and SAR studies of novel cyclopentaquinoline derivatives as DNA intercalators, topoisomerase II inhibitors, and apoptotic inducers

Hammoud, M. M., Nageeb, A. S., Morsi, M. A., Gomaa, E. A., Elmaaty, A. A., & Al-Karmalawy, A. A. (2022) · New Journal of Chemistry · doi:10.1039/d2nj01646j · Cited by 56

Lipid metabolism and Calcium signaling in epithelial ovarian cancer

Kouba, S., Ouldamer, L., Garcia, C., Fontaine, D., Chantôme, A., Vandier, C., Goupille, C., & Potier‐Cartereau, M. (2019) · Cell Calcium · doi:10.1016/j.ceca.2019.06.002 · Cited by 56

Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer

Tailor, D., Resendez, A., Garcia-Marques, F. J., Pandrala, M., Going, C. C., Bermudez, A., Kumar, V., Rafat, M., Nambiar, D. K., Honkala, A. T., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.014 · Cited by 55

NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis

Zhu, M., Yang, L., & Wang, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s257311 · Cited by 54

NOTCH signalling in ovarian cancer angiogenesis

Fidalgo, J. A. P., Ortega-Morillo, B., Simón, S., Samartzis, E. P., & Boussios, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4497 · Cited by 52

Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer

Liu, J., Jiao, X., & Gao, Q. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.015 · Cited by 52

Biological evaluation, docking studies, and in silico ADME prediction of some pyrimidine and pyridine derivatives as potential EGFR WT and EGFR T790M inhibitors

Al-Warhi, T. I., Al-Karmalawy, A. A., Elmaaty, A. A., Alshubramy, M. A., Abdel‐Motaal, M., Majrashi, T. A., Asem, M., Nabil, A., Eldehna, W. M., & Sharaky, M. M. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2135512 · Cited by 51

Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment

Yi, X., Liu, Y., Zhou, B., Xiang, W., Deng, A., Fu, Y. H. H., Zhao, Y., Ouyang, Q., Liu, Y., Sun, Z., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111013 · Cited by 50

Tumour-associated macrophages heterogeneity drives resistance to clinical therapy

Guo, S., Chen, X., Guo, C.-H., & Wang, W. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.8 · Cited by 49

Cancer-associated mesothelial cell–derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis

Bajwa, P., Kordylewicz, K., Bilecz, A. J., Lastra, R. R., Wroblewski, K., Rinkevich, Y., Lengyel, E. R., & Kenny, H. A. (2023) · JCI Insight · doi:10.1172/jci.insight.163019 · Cited by 49

miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance

Wang, X., Jiang, L., & Liu, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03422-7 · Cited by 48

Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase

Hudson, L. G., Gillette, J. M., Kang, H., Rivera, M. R., & Wandinger‐Ness, A. (2018) · Cancers · doi:10.3390/cancers10100358 · Cited by 47

Gene expression profiles and pathway enrichment analysis to identification of differentially expressed gene and signaling pathways in epithelial ovarian cancer based on high-throughput RNA-seq data

Siavoshi, A., Taghizadeh, M., Dookhe, E., & Piran, M. (2021) · Genomics · doi:10.1016/j.ygeno.2021.11.031 · Cited by 46

Cyclooxygenase 2 Promotes Proliferation and Invasion in Ovarian Cancer Cells via the PGE2/NF-κB Pathway

Zhang, X., Yan, K., Deng, L., Liang, J., Liang, H., Feng, D., & Ling, B. (2019) · Cell Transplantation · doi:10.1177/0963689719890597 · Cited by 44

Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology

Brown, Y., Hua, S., & Tanwar, P. S. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.02.004 · Cited by 47

New insights into the interaction between m6A modification and lncRNA in cancer drug resistance

Jin, Y., & Fan, Z. (2023) · Cell Proliferation · doi:10.1111/cpr.13578 · Cited by 42

Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease

Nath, S., Saad, M. A., Pigula, M. L., Swain, J. W. R., & Hasan, T. G. (2019) · Cancers · doi:10.3390/cancers11121887 · Cited by 40

Identification of Immune-Related Key Genes in Ovarian Cancer Based on WGCNA

Quan, Q., Xiong, X., Wu, S., & Yu, M. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.760225 · Cited by 41

Sodium molybdate inhibits the growth of ovarian cancer cells via inducing both ferroptosis and apoptosis

Mao, G., Xin, D., Wang, Q., & Lai, D. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.02.023 · Cited by 40

Targeting tumor‑associated macrophages: Critical players in tumor progression and therapeutic strategies (Review)

Su, P., Li, O., Ke, K., Jiang, Z., Wu, J., Wang, Y., Mou, Y., & Jin, W. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5648 · Cited by 44

MuvB: A Key to Cell Cycle Control in Ovarian Cancer

Iness, A. N., & Litovchick, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00223 · Cited by 36

Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells

Shi, S., Huang, X., Ma, X., Zhu, X., & Zhang, Q. (2020) · PLoS ONE · doi:10.1371/journal.pone.0225290 · Cited by 34

METTL3 ‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K / AKT pathway

Cui, S. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24761 · Cited by 34

Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer

Zhang, Q., Chen, X., Cao, J., Yang, W., Wan, G., Feng, Q., Zhou, S., Yang, H., Wang, N., Liu, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01370 · Cited by 35

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging

Morosi, L., Matteo, C., Ceruti, T., Giordano, S., Ponzo, M., Frapolli, R., Zucchetti, M., Davoli, E., D’Incalci, M., & Ubezio, P. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41395 · Cited by 32

S -Alkylated quinazolin-4(3 H )-ones as dual EGFR/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study

Tawfik, S. S., Hamdi, A., Ali, A. R., Elgazar, A. A., El-Shafey, H. W., El‐Azab, A. S., Bakheit, A. H. H., Hefnawy, M., Ghabbour, H. A., & Abdel‐Aziz, A. A. ‐. (2024) · RSC Advances · doi:10.1039/d4ra04828h · Cited by 31

Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules

Zhang, X., Ding, Y., Chen, J., Xiao, X., Zhang, W., Zhou, L., Kong, Q.-W., Shi, M., Yang, J., Jiang, B., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113067 · Cited by 31

Spatial Distribution Control of Antimicrobial Peptides through a Novel Polymeric Carrier for Safe and Efficient Cancer Treatment

Kang, Z., Wang, C., Zhang, Z., Liu, Q., Zheng, Y., Zhao, Y., Pan, Z., Li, Q., Shi, L., & Liu, Y. (2022) · Advanced Materials · doi:10.1002/adma.202201945 · Cited by 31

MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer

Li, Y., Tian, W., Zhang, H., Zhang, Z., Zhao, Q., Chang, L., Lei, N., & Zhang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830570 · Cited by 31

High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy

Posabella, A., Köhn, P., Lalos, A., Wilhelm, A., Mechera, R., Soysal, S. D., Muenst, S. E., Güth, U., Stadlmann, S., Terracciano, L., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03108-6 · Cited by 30

Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer

Reyes, M. E., la Fuente, M. D., Hermoso, M. A., Ili, C., & Brebi, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00901 · Cited by 30

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers

Page, C. L., Amuzu, S., Rahimi, K., Gotlieb, W. H., Ragoussis, J., & Tonin, P. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.005 · Cited by 30

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

Chesnokov, M. S., Khan, I., Park, Y., Ezell, J., Mehta, G., Yousif, A., Hong, L., Buckanovich, R. J., Takahashi, A., & Chefetz, I. (2021) · Cancers · doi:10.3390/cancers13061369 · Cited by 29

The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer

Wang, Y., Huang, Z., Li, B., Liu, L., & Huang, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.863541 · Cited by 30

Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies

Andrade, J., Gallagher, A., Maharaj, J., & McClelland, S. E. (2023) · Chromosome Research · doi:10.1007/s10577-023-09737-5 · Cited by 35

Copper in Gynecological Diseases

Conforti, R. A., Delsouc, M. B., Zorychta, E., Telleria, C. M., & Casais, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417578 · Cited by 31

Damnacanthal isolated from morinda species inhibited ovarian cancer cell proliferation and migration through activating autophagy

Li, R., Li, H., Lan, J., Yang, D., Lin, X., Xu, H., Han, B., Yang, M., Su, B., Liu, F., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154084 · Cited by 27

SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells

Ha, C., Hu, L., Ren, Y., Yang, J., & Xin, L. (2022) · Medical Oncology · doi:10.1007/s12032-022-01763-3 · Cited by 26

Phototheranostics: An advanced approach for precise diagnosis and treatment of gynecological inflammation and tumors

Ding, Q., Guo, A., Zhang, S., Gu, C., Wang, X., Li, X., Gu, M., & Kim, J. S. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123012 · Cited by 26

LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer

Feng, L., Huang, Y., Zhang, W., & Li, L. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00807-y · Cited by 27

The antitumor properties of atractylenolides: Molecular mechanisms and signaling pathways

Jiang, Y., Guo, K., Wang, P., Zhu, Y., Huang, J., & Ruan, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113699 · Cited by 27

Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy

Sun, J., Bao, S., Xu, D., Zhang, Y., Su, J., Liu, J., Hao, D., & Zhou, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1874-9 · Cited by 23

MicroRNA-320a Promotes Epithelial Ovarian Cancer Cell Proliferation and Invasion by Targeting RASSF8

Zhang, L., Chen, H., He, F., Zhang, S., Li, A., Zhang, A., & Zhang, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.581932 · Cited by 24

Development and Validation of a Novel Histone Acetylation-Related Gene Signature for Predicting the Prognosis of Ovarian Cancer

Dai, Q., & Ye, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.793425 · Cited by 24

Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis

Zhang, X., Li, Y., Ma, H., & Gao, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-63396-8 · Cited by 24

EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer

Sun, S., Yang, Q., Cai, E., Huang, B., Ying, F., Wen, Y., Cai, J., & Yang, P. (2020) · PeerJ · doi:10.7717/peerj.9052 · Cited by 24

Tissue-based long non-coding RNAs “PVT1, TUG1 and MEG3” signature predicts Cisplatin resistance in ovarian Cancer

El-Khazragy, N. N., Mohammed, H. F., Yassin, M., Elghoneimy, K. K., Bayoumy, W., Hewety, A. A., Magdoub, H. M. E., Elayat, W. M., Zaki, W. S., Safwat, G., et al. (2020) · Genomics · doi:10.1016/j.ygeno.2020.08.005 · Cited by 23

Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness

Huang, Z., Byrd, O., Tan, S., Hu, K., Knight, B., Lo, G., Taylor, L., Wu, Y. S., Berchuck, A., & Murphy, S. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-48485-8 · Cited by 23

Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer

Koc, Z. C., Sollars, V. E., Zgheib, N. B., Rankin, G. O., & Koc, E. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129352 · Cited by 22

PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway

Wu, J., Wu, Y., Chen, S., Guo, Q., Shao, Y., Liu, C., Lin, K., Wang, S., Zhu, J. W., Chen, X., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02943-3 · Cited by 24

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Rendell, A., Thomas-Bland, I., McCuish, L., Taylor, C., Binju, M., & Yu, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10092113 · Cited by 21

Ferroptosis in epithelial ovarian cancer: a burgeoning target with extraordinary therapeutic potential

Ruan, D., Wen, J., Fang, F., Lei, Y., Zhao, Z., & Miao, Y. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01721-6 · Cited by 21

The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer

Patel, M., Wang, Y., Bartom, E. T., Dhir, R., Nephew, K. P., Matei, D. E., Murmann, A. E., Lengyel, E. R., & Peter, M. E. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0953 · Cited by 20

The Roles of Exosomes in Ovarian Cancer Chemo-resistance

Liu, Y., Xiao, L., Zhang, T., & Liu, G. (2023) · Journal of Cancer · doi:10.7150/jca.84930 · Cited by 20

Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review

Alemzadeh, E., Allahqoli, L., Mazidimoradi, A., Alemzadeh, E., Ghasemi, F., Salehiniya, H., & Alkatout, İ. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.031006 · Cited by 19

Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines

Losi, L., Lauriola, A., Tazzioli, E., Gozzi, G., Scurani, L., D’Arca, D., & Benhattar, J. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0536-y · Cited by 19

CCAAT enhancer binding protein α suppresses proliferation, metastasis, and epithelial-mesenchymal transition of ovarian cancer cells via suppressing the Wnt/β-catenin signaling

Zhang, L., Mo, L., Tian, C.-C., Wang, T.-T., & Mi, S.-F. (2021) · Neoplasma · doi:10.4149/neo_2021_210103n2 · Cited by 17

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled In Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers

Marson, D., Laurini, E., Aulić, S., Fermeglia, M., & Pricl, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070351 · Cited by 18

A stearate-rich diet and oleate restriction directly inhibit tumor growth via the unfolded protein response

Ogura, J., Yamanoi, K., Ishida, K., Nakamura, E., Ito, S., Aoyama, N., Nakanishi, Y., Menju, T., Kawaguchi, K., Hosoe, Y., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01356-2 · Cited by 22

The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo

Grimes, M. M., Kenney, S. R., Dominguez, D. R., Brayer, K. J., Guo, Y., Wandinger‐Ness, A., & Hudson, L. G. (2021) · BMC Cancer · doi:10.1186/s12885-020-07716-1 · Cited by 17

The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer

Xu, Z., Peng, B., Kang, F., Zhang, W.-Q., Xiao, M., Li, J., Hong, Q., Cai, Y., Liu, W., Yan, Y., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.877254 · Cited by 17

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial

Sabatier, R., Garnier, S., Guillé, A., Carbuccia, N., Pakradouni, J., Adélaı̈de, J., Provansal, M., Cappiello, M., Rousseau, F., Chaffanet, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.946257 · Cited by 17

LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer

Zhu, X., Shijing, Y. O. U., Du, X., Song, K., Lv, T., Zhao, H., & Yao, Q. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01435-9 · Cited by 20

Immunotherapeutic Approaches in Ovarian Cancer

Yoon, H., Kim, A., & Jang, H. S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020081 · Cited by 16

Ecological and evolutionary dynamics to design and improve ovarian cancer treatment

Han, G. Y. Q., Alexander, M., Gattozzi, J., Day, M., Kirsch, E. P., Tafreshi, N. K., Chalar, R., Rahni, S., Gossner, G., Burke, W. J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70012 · Cited by 16

3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function

Jin Wei, L. U., Yingchun, W., Zhujun, S., Wu, Y., Wu, D., Yu, H., Xi, Y., Wanzhou, Z., Buluan, Z., & Jinhua, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108992 · Cited by 16

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part II: Self-Assembled siRNA Nanocarriers

Laurini, E., Marson, D., Aulić, S., Fermeglia, M., & Pricl, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070324 · Cited by 16

Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations

Lee, A. H., Peña, C. M., & Dawson, M. (2022) · Cancers · doi:10.3390/cancers14061418 · Cited by 17

SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer

Zheng, Z., Li, X., Yang, B., Xu, Q., Zhu, X., Hu, L.-P., & Teng, Y. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01075-3 · Cited by 15

Puerarin induces platinum-resistant epithelial ovarian cancer cell apoptosis by targeting SIRT1

Duan, J., Yin, M., Shao, Y., Zheng, J., & Nie, S. (2021) · Journal of International Medical Research · doi:10.1177/03000605211040762 · Cited by 15

Silencing of NLRP3 Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin

Li, W., Zhao, X., Zhang, R., Xie, J., & Zhang, G. (2023) · Mediators of Inflammation · doi:10.1155/2023/7700673 · Cited by 14

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Fashemi, B., van Biljon, L., Rodriguez, J., Graham, O., Mullen, M., & Khabele, D. (2023) · Journal of Visualized Experiments · doi:10.3791/65068 · Cited by 15

Modulation of Cisplatin Sensitivity through TRPML1-Mediated Lysosomal Exocytosis in Ovarian Cancer Cells: A Comprehensive Metabolomic Approach

Kim, B., Kim, G., Kim, H., Song, Y. S., & Jung, J. (2024) · Cells · doi:10.3390/cells13020115 · Cited by 14

MiR-124-3p.1 Sensitizes Ovarian Cancer Cells to Mitochondrial Apoptosis Induced by Carboplatin

Deng, X., Chen, Y., Liu, Z., & Xu, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s242342 · Cited by 14

Development and Verification of an Autophagy-Related lncRNA Signature to Predict Clinical Outcomes and Therapeutic Responses in Ovarian Cancer

Li, Y., Wang, J., Wang, F., Gao, C., Cao, Y., & Wang, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.715250 · Cited by 13

Identification of a novel nine‐SnoRNA signature with potential prognostic and therapeutic value in ovarian cancer

Zhu, W., Zhang, T., Luan, S., Kong, Q., Hu, W., Zou, X., Zheng, F., & Han, W. (2022) · Cancer Medicine · doi:10.1002/cam4.4598 · Cited by 13

Microphysiological systems as models for immunologically ‘cold’ tumors

Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14

Arborinine suppresses ovarian cancer development through inhibition of LSD1

Li, N., Yang, L., & Zuo, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120275 · Cited by 12

NTNG1 Modulates Cisplatin Resistance in Epithelial Ovarian Cancer Cells via the GAS6/AXL/Akt Pathway

Fang, S., Luo, Y., Zhang, Y., Wang, H., Liu, Q., Li, X., & Yu, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.652325 · Cited by 12

Identifying Mitotic Kinesins as Potential Prognostic Biomarkers in Ovarian Cancer Using Bioinformatic Analyses

Liu, H., Chen, C., Fehm, T. N., Cheng, Z., & Neubauer, H. J. (2022) · Diagnostics · doi:10.3390/diagnostics12020470 · Cited by 11

Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer

Chesnokov, M., Yadav, A., & Chefetz, I. (2022) · bioRxiv · doi:10.3390/ijms232113365 · Cited by 7

The Novel Zinc Finger Protein 587B Gene, ZNF587B, Regulates Cell Proliferation and Metastasis in Ovarian Cancer Cells in vivo and in vitro

Liu, Y., Ouyang, Q., Sun, Z., Tan, J., Huang, W., Liu, J., Liu, Z., Zhou, H., Zeng, F., & Liu, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s252347 · Cited by 11

Nanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation

Wang, C., Li, Q., Song, K., Wang, W., Zhang, N., Dai, L., & Di, W. J. (2024) · Nanoscale Advances · doi:10.1039/d4na00227j · Cited by 10

Abstract IA12: Acquired chemotherapy resistance in high-grade serous ovarian cancer patients

Christie, E. L., Beach, J. A., Etemadmoghadam, D., Garsed, D. W., Patch, A., Fereday, S., Pattnaik, S., Study, A. O. C., Brady, S. W., Bild, A. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1557-3265.ovca17-ia12

Abstract IA04: Drug resistance in end-stage high-grade serous ovarian cancer

Christie, E. L., Alsop, K., Au‐Yeung, G., Pandey, A., Study, A. O. C., & Bowtell, D. D. L. (2020) · Clinical Cancer Research · doi:10.1158/1557-3265.ovca19-ia04 · Cited by 1

Abstract 2984: Heterogeneous mechanisms of acquired resistance in high grade serous ovarian cancer

Bowtell, D. D. L. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2984

Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.

Christie, E. L., Beach, J. A., Etemadmoghadam, D., Garsed, D. W., Patch, A., Fereday, S., Pattnaik, S., Brady, S. W., Bild, A. H., & Bowtell, D. D. L. (2018) · Clinical Cancer Research

Whole–genome characterization of chemoresistant ovarian cancer

Patch, A., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P. A., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,572